- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04478578
Incidences, causes et résultats des maladies fébriles dans les régions rurales d'Asie du Sud et du Sud-Est (SEACTN-WP-A)
Détermination de l'incidence, des causes et des résultats des maladies fébriles rurales (RFI) en Asie du Sud et du Sud-Est, dans le cadre du réseau d'essais communautaires d'Asie du Sud et du Sud-Est (SEACTN). Lot de travaux A (WP-A).
The study will collect information to understand the causes and outcomes of febrile illness in rural areas in countries across South and Southeast Asia (including Cambodia, Laos, Myanmar and Bangladesh). The findings will be used to identify new tests and treatments that can improve the management of febrile patients in the future.
This study is funded by the UK Wellcome Trust. The grant reference number is 215604/Z/19/Z
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This study aims to better understand and quantify the burden of febrile illness, the aetiological causes and the manner in which it affects the people living in rural areas in South and Southeast Asia, all on a scale which has not been attempted before. The SEACTN RFI project will collect information to help better understand and predict these outcomes based on a multitude of factors, which will form the basis for interventions within the network in the future. Determining the incidence, causes and outcomes of febrile illness in these settings will be done through two work packages. The first of these, Work Package A (WP-A), the subject of this study, will be carried out at the community level, primarily by engaging village health worker (VHWs) and low-level Health Centres (HCs) which serve the communities to recruit patients presenting with a febrile illness. These patients will be assessed for presenting symptoms and followed up for clinical outcomes. Collection of specimen for diagnostic investigations in these settings is challenging. Currently, mRDTs are conducted by VHWs and HCs in these networks, therefore by using the same process, but also applying blood to filter paper and allowing it to dry (DBS), investigators will test for certain other pathogens, which will increase the aetiological yield.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Dhaka, Bengladesh, 1212
- Building Resources Across Communities (BRAC)
-
-
-
-
-
Yangon, Birmanie, 11201
- Medical Action Myanmar (MAM)
-
-
-
-
-
Battambang, Cambodge
- Action for Health Development (AHEAD)
-
-
-
-
Vientiane Prefecture
-
Vientiane, Vientiane Prefecture, Laos, 01000
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU)
-
-
-
-
-
Chiang Rai, Thaïlande, 57000
- Chiangrai Clinical Research Unit (CCRU)
-
-
Bangkok
-
Ratchathewi, Bangkok, Thaïlande, 10400
- Mahidol VivaResearch Unit, Faculty of Tropical Medicine, Mahidol University (MVRU)
-
-
Changwat Tak
-
Mae Sot, Changwat Tak, Thaïlande, 63110
- Shoklo Malaria Research Unit (SMRU)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with an acute febrile illness of all ages presenting to village health workers (VHWs) or peripheral health facilities.
La description
Inclusion Criteria:
- Documented fever (≥ 37.5°C axillary), hypothermia (< 35.5°C) and/or history of fever in the last 24 hours.
- Willingness and ability to comply with study protocol for the study duration.
- Written informed consent given to participate in the trial.
Exclusion Criteria:
- Currently enrolled in the study
- Accident or trauma is the cause for presentation
- Presentation ≤ 3 days after routine immunisations
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Patients with febrile illness
Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Local incidence of febrile illness
Délai: From Months 0 to 24
|
The incidence per year that an individual seeks care for a febrile illness with the village health workers or local health facility, at the village level. |
From Months 0 to 24
|
|
Overall incidence of febrile illness
Délai: From Months 0 to 24
|
The incidence per year that an individual seeks care for a febrile illness with the village health workers or local health facility, at the regional level. These estimates will later be triangulated with and extrapolated from using health seeking behavior surveys for an estimate of the total incidence of febrile illness. |
From Months 0 to 24
|
|
Mortality
Délai: Within approximately 1 month of first presentation to the village health worker or health facility
|
Case fatality rates in febrile illness |
Within approximately 1 month of first presentation to the village health worker or health facility
|
|
Morbidity
Délai: Over 1 month after first presentation
|
Duration of illness in patients presenting with a fever to the village health worker or health facility. |
Over 1 month after first presentation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Prevalence of pathogens in febrile patients
Délai: Samples collected over approximately 24 months
|
Pathogens will be detected in patients presenting over a 24 month period using point of care tests and diagnostic assays on acute and convalescent dried blood spots. |
Samples collected over approximately 24 months
|
|
The correlation between host biomarker concentrations, aetiological diagnoses and clinical outcomes.
Délai: Samples collected over approximately 24 months
|
The area under the curve, sensitivity and specificity of host biomarkers to identify bacterial infections and to predict severe outcomes. |
Samples collected over approximately 24 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Yoel Lubell, Prof, Mahidol Oxford Tropical Medicine Research Unit
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- BAC20001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Data collected for this study will be under the custodianship of MORU. With participant's consent, data from this study may be shared in a de-identified form with other groups or researchers in accordance with the MORU Data Sharing Policy.
Délai de partage IPD
After completion of trial activities and reporting
Critères d'accès au partage IPD
MORU Data Sharing Policy. (http://www.tropmedres.ac/data-sharing-policy)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .